Table 1.
Patients’ overview. Three main sub-groups of patients have been included in the study: Acute Lymphoblastic Leukemia (ALL) patients, Multiple Myeloma (MM) patients and MM patients treated with chimeric antigen receptor (CAR)- T cells.
| Patients | Samples | Age (range) | Gender | |
|---|---|---|---|---|
| ALL | 25 | 69 | 46 (20-77) | F2 35%-M 65% |
| MM | 91 | 150 | 61 (39-76) | F 44%-M 56% |
| CAR-T1 | 9 | 14 | 54 (38-64) | F 36%-M 64% |
| Tot | 125 | 233 | 54 (20-77) | F 38%-M 62% |
1CAR-T is referred only to MM patients who were sampled after at least 56 days after anti-BCMA CAR-T infusion (median: 171 days; range: 56-365 days); 2F, female and M, male.